PREVENTION OF HEPATITIS A IN SOLDIERS

File: 970107_sep96_decls33_0007.txt
Page: 0007
Total Pages: 7

Subject: PREVENTION OF HEPATITIS A IN SOLDIERS                           

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003205

Folder Title: HEPATITIS A - VACCINES                                                                          

Document Number:          1

Folder Seq  #:         62



                       The cc-nany has indicated that larme quantities of
                   vaccine c(. d be made available if ne id. This vaccine
                   would be available in approximately 4 months. Availability
                   of research lots is being ascertained.

                   3. WRAIR Research Plans

                        Plans have been developed to evaluate this vaccine at
                   Schofield Barracks. Evaluation of a 0, 6 and 0, 12 month
                   schedule using both the 200 and 400 ng products have been
                   planned. With blood specimens being drawn shortly after
                   the initial dose, data on the immune response to one dose
                   would be available. In addition, short immunization
                   schedules have been formulated. (0, 14 days, 0, 30 days,
                   and a double dose at time 0). Data from these studies
                   would be available by the end of March.

                   4. Recommendation for use of MSD vaccine

                      a. Defer fielding of this vaccine until at least 500
                      successful, safe immunizations have been completed.




               C.  WRAIR's vaccine


                   1. Status of development

                        An IND exemption is in place. Further studies of the
                   crude prototype were carried out at Ft. Lewis. The vaccine
                   was 90% immunogenic, regardless of whether 3 or 4 doses
                   were used. A decision was made to proceed with development
                   of a more highly purified vaccine.
                        The Salk Institute is producing the WRAIR vaccine.
                   Our large scale production method for a highly purified
                   vaccine is still being developed.

                   2. Availability

                        This vaccine is unavailable for large scale use at
                   this time.




II. HOKE, JR
                                       COL, MC
                                       Chairman
                                       USAMRDC Hepatitis Steering Committee*













                                             6

Document 7 f:/Week-36/BX003205/HEPATITIS A - VACCINES/prevention of hepatitis a in soldiers:01029715472734
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003205
Unit = OTSG
Parent Organization = HSC
Folder Title = HEPATITIS A - VACCINES
Folder Seq # = 62
Subject = PREVENTION OF HEPATITIS A IN SOLDIERS
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997